Torreya Insights

Report
TORREYA INSIGHTS
Torreya Insights is a professional and data services company spun out of Torreya Partners, a New York-based
boutique, financial advisory firm. We assist life science companies in all aspects of the business
development process. Our consulting engagements usually focus on helping our clients raise capital, locate
suitable assets for acquisition, or find potential partners for further asset development. We also perform
financial valuations, market assessment, and quantitative fairness opinion analyses.
Our data services include subscriptions to three databases: AvaRx, Licensing Dynamics, and Financing
Dynamics.
• AvaRx is a searchable dynamic database of more than 2,000 licensing opportunities across various
therapeutic areas and stages of development.
• Licensing Dynamics is a Customer Relation Management (CRM) database designed for pharmaceutical
industry out-licensing, which has contact information of over 16,000 executives.
• Financing Dynamics is designed to assist our clients in raising capital, and contains information on about
900 funds and 3,000 investors.
Torreya Insights' team members have deep industry knowledge and connections. Our reputation is built on
quality advice and positive outcomes for our clients.
2
AVARX
WWW.AVARX.COM
About AvaRx:



AvaRx is a searchable, dynamic database of business development opportunities in the pharmaceutical industry.
The name is an abbreviation of “Available Pharmaceutical Products” and is pronounced “A (as in apple)-Va-Rex.”
AvaRx launched in December 2013 and is maintained by Torreya Insights staff.
Benefits:




Simple to use
No initial cost - any registered user may search for opportunities and/or list an opportunity
Continually curated and subjected to quality controls
•
•
Staff of highly educated experts adding and reviewing information
Partnership with Torreya Partners, a leading life sciences advisor, enhances timelineness and
quality of information
The information is substantially more useful than that which is found in other information services that
have pharmaceutical business development opportunities:
•
Most other services catalog thousands of assets in development – some of which could be good
candidates for licensing deals, but do not isolate actionable, fresh business development
opportunities
3
GETTING AN ACCOUNT
If you don’t have an account:







Go to the AvaRx site
www.avarx.com
Click on “Become a Free
Member” or “Join / Sign Up”
Fill in your information, including
your name and company
Click the “Register” button
Your account will be created and
you will be logged in
automatically
You can go to “My AvaRx” and fill
out more information
You are now ready to search for
opportunities
4
MANAGING YOUR STATUS


The first time that you log in to AvaRx, you become a
“Registered User,” at no cost. With this status, you can:


Search through over 1,000 opportunities

List one asset
View very detailed information on those
opportunities
Upgrading to “Premium Subscriber” enables you to:



Search for additional opportunities
AvaRx’s “Freemium” subscription
structure allows for free searches of a
large number of business
development opportunities.
List more than one asset
View contact information for each asset
5
BENEFITS OF A PREMIUM SUBSCRIPTION
Searching for assets






Listing assets
Proprietary listings – Over 600, mostly late
stage or less obvious opportunities.


Undisclosed listings – Approximately 30
highly actionable listings through Torreya
Insights contacts.

Non-confidential presentations and other
documents (over 2,000).
Contact details of business development
professionals.
Excel/PDF Export – Export list of results from
searches to an accessible format.
Messaging – Contact counterparties using
the My AvaRx messaging system to set up
meetings about opportunities.

List unlimited number of assets.
List undisclosed assets (manage
confidentiality).
Access buy-side preferences and
contacts through a Customer
Relationship Management database,
Licensing Dynamics.
Access analytic tool to see who is
viewing your asset/s.
Other benefits:
 High impact advice (teaser
feedback, call list generating)
from our experienced staff.
 Monthly calls with bankers of
new and exciting listings.
PRICING AND BENEFITS COMPARISON
Registered
User
Premium
(Single User)
Premium
(Corporate)
Free
$2,500*
$6,000#
Number of Seats†
1
1
3
Number of Undisclosed Item Calls / Month
0
3
9
Number of Listings to Create
1
Up to 25
Unlimited
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
Benefits Comparison
Quarterly Subscription Rate
Access Over 1,000 Listings
Search by Indication, Phase of Development, etc.
Screen Buyside Dealmakers / Get Contacts
Access Analytical Reports on Your Listings
Access to Messaging
Access Proprietary Listings
Access Non-Confidential Documents
Access Contact Information for Opportunities
* $8,000 per annum if prepaid.
#
$20,000 per annum if prepaid.
† Pricing for large enterprise subscriptions is available upon request
7
SEARCH FIELDS

Refine searches in several categories:
•
•
•
•


•
•
•
Therapeutic area (“TA”) - e.g., Urology,
Endocrinology
Indication - e.g., Alzheimer’s Disease
Development phase - e.g., Phase I
Situation - e.g., Licensing Opportunity,
Generic Drug
Territories available - e.g., Worldwide, China
Molecule type - e.g., Antibody
Route of Administration - e.g., Intravenous
Form very specific queries (e.g. “Phase 1,
Urology, Rights Available - Japan.”)
Carry out text searches – by drug name,
company name, etc.
8
NAVIGATING THE SEARCH RESULT PAGE
Search assets in the
Opportunities page.
You can search by drug
name.
You can refine a search by
narrowing or expanding
search terms.
Also search by Company,
Therapeutic Area, and Situation
This button allows you to save a
search. Saved searches can be
viewed in “My AvaRx”.
If you “peek” you
can see a brief
profile.
Quick description
Customize searches by
checking and unchecking
category search terms.
Clicking “more” expands
the list of visible search
terms within a category.
Terms are listed in
descending order of the
number of such asset
types found in AvaRx.
The pen icon opens a
more extensive,
alphabetized search page
for the creation of
compound searches.
Share this item with
a colleague (via
email).
You can track
developments for a
specific asset. This
is also a good way
to bookmark.
“More” opens up a
detailed profile of
the asset.
9
NAVIGATING THE PRODUCT LISTING
Clicking “Company
Profile” gets all
information in Avarx on a
company.
Company address, phone
and web site. Also a link
to Google maps in order
to get directions.
This is the right contact
for BD discussions,
including phone and email
details.
Non-confidential
documents on the
business development
opportunity, including a
non-confidential overview
and scientific posters.
Name of company and
drug candidate
“Track It” allows you to follow
this listing over time
Summary of key details,
including phase of
development, TA, indications,
territories available and
situation
Overview of the business
development opportunity,
including disease state, name of
drug and pertinent details on a
deal.
Description of MOA, biology,
chemistry work and links to
publications, if available.
Narrative history of clinical trial
work, including outcomes. If the
compound is preclinical, then
preclinical data will be
discussed.
Description of territories
where the opportunity is
already licensed.
10
THERAPEUTIC AREAS
Search using 47 therapeutic areas (TA’s). The AvaRx TA taxonomy is different than the ICD-9 system, which
is organ-centric. In particular, while the primary focus is on organ system classification (e.g.,
Gastroenterology), there is also reference to major areas of disease etiology (e.g., Infectious disease- viral,
Fibrosis). The AvaRx TA terms are intended to match the interests of pharmaceutical business
development professionals who often search for opportunities that match physician groupings (e.g.,
Endocrinologists, Pediatricians), rather than organ systems per se. There are also a few TA’s included that
specify the end customer for a product (Animal Health, Biodefense).
11
INDICATIONS
Search over 500 disease indications. We have set indications generally by the disease descriptions
employed by the companies listed in our database. Some indications, such as “Acetaldehyde Toxicity,” are
rarely used, whereas others, such as “Parkinson’s Disease,” are very common. Wherever possible, we
attempt to consolidate identical indications such as HIV and AIDS into “HIV / AIDS.” We have also included
some catch-all indications, such as “Neurodegenerative Diseases (General).” However, when listing or
searching, it is best to use specific terms.
12
DEVELOPMENT PHASES
There are seven phases of development of a drug candidate - starting in the research phase and ending in
the marketing phase.
Research / Discovery Phase
Conducting chemistry and biology work on potential drug candidates, but a lead candidate has not yet entered pharmacology
studies.
Preclinical
Includes situations where a lead drug candidate has entered pharmacology studies all the way up to the point where an IND is active
but no humans have been tested with a drug.
Phase I
First human studies have begun on a drug candidate. This includes situations up to where a dose-ranging Phase 2 study has begun.
Quite a few companies (particularly in oncology) refer to first studies in patients at Phase I/II trials. We generally classify these as
Phase Ib studies and include them in Phase I, unless there is an active comparator in use or a large number of patients studies in a
multiple ascending dose setting.
Phase II IIa IIb
Dose ranging and dose confirmation studies have begun. This covers situations where Phase II studies for a drug candidate are just
beginning to when a company has completed Phase II studies but has not yet commenced Phase III studies.
Phase III
Either starting Phase III, in Phase III trials or has completed Phase III trials without having yet applied for regulatory approval.
NDA/BLA Filed
Pivotal studies for a drug have been completed and a company has filed for regulatory approval anywhere in the world.
On Market
A drug candidate has been approved and is either commercially available or soon to be available anywhere in the world.
13
ROUTES OF ADMINISTRATION / MOLECULE TYPE
You can search by route of administration (e.g., intranasal, oral).
There are seventeen labels for route of administration.
Catheter
Implant
Inhalation
Injection
Intraocular
Intrathecal
Intratracheal
Intravaginal
Intravenous
Intravesical
Nasal
Oral
Rectal
Sublingual/buccal
Topical
Transdermal
Unknown
You can also search by type of molecule (e.g., small molecule,
antibody). There are five types of molecules.
Antibody
Other Macromolecule
Peptide
Protein
Small Molecule
Most cases where “other macromolecule” is referred
to constitute vaccines or some type of RNA-based
therapy.
14
TERRITORIES (Rights Available)
We have divided the world into 14 territories and have included one catch-all for worldwide rights. If a
product has worldwide rights listed, this means that the business development opportunity has yet to be
regionalized and there are likely no licensing deals signed yet. We selected the territories based on the
size of pharma consumption by territory and the history of requests for regional rights to products at
Torreya Insights.
Territories For Search
Worldwide
Africa
Asia ex China Korea Japan
Australia/New Zealand
Canada
China
Europe
India
Japan
Korea
Latin America
Middle East
Russia and CIS
Turkey
USA
Russia & CIS
Canada
Europe
USA
Turkey
China
Mid
East
Africa
Latin
America
Korea
Japan
Asia except
CH JP KR
India
Australia and
New Zealand
!
Key Point: If you would like to search everything available in Europe,
you have to search for Worldwide and Europe.
15
SITUATION FIELDS
Situations Describe Aspects of a Search That Go Beyond Phase of Development and Therapeutic Areas
Many users of AvaRx look beyond therapeutic areas or development phase for specific situations that fit a
business strategy. We have attempted to capture these situations based on dialogue with users over the
years.
There are 40 situation types (e.g., active sale process, mature branded products).
Cancer / Oncology Situations
In addition, AvaRx includes hundreds of opportunities in oncology. Thus, navigating the available oncology
business development opportunities is challenging. We have found that many licensing professionals
focused on oncology are interested in specific strategies for stopping cancer (e.g., altering cancer
metabolism). As a result, to ease the search process, we have classified oncology business development
opportunities into a number of strategies for slowing cancer.
16
SITUATION FIELDS
Situation
Description
505 (b) 2 Product
A drug being developed with little change from a previously approved drug (change in dose, administration,
combination, active ingredient, Rx to OTC) through an expedited approval pathway.
Active Process (Sale or
Licensing)
The company is known to be running an active business development process, typically with the help of an
external financial advisor.
Big Pharma / Biotech
A top 20 pharmaceutical company is out-licensing a drug candidate or mature product.
Programs for Out-licensing
Bigger Deal ($200mm+)
Refers to potential transactions where the expected value exceeds $200 million.
Biosimilar Drug
Biosimilars or (follow-on biologics) are terms used to describe officially approved subsequent versions of
innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry
on the innovator product.
Cell Therapy
A situation where a cellular product is used for medicinal purposes. Often, a cell therapy involves an
autologous therapy where a patient's own cells are removed, processed and then reinserted with expected
benefit.
Diagnostic
AvaRx also includes many diagnostic opportunities. Typically, we include therapeutically-relevant molecular
diagnostics, but other types are also included.
Diagnostics - Imaging
Refers to the availability of an imaging technology with a diagnostic purpose.
Distressed Situation
Assets that are held by bankrupt, financially distressed or restructured companies are identified by this
situation flag. Often, the intellectual property of an asset remains available long after a company ceases to
operate. AvaRx includes a number of distressed assets as certain buyers specifically seek bargains based on
companies that have encountered operational or financial difficulty.
Drug Delivery Technology
This flags technologies that are available to deliver a drug in a novel way. Drug delivery technologies include:
Transdermal Patches, Inhalables, Needle-Free Injectables, Subcutaneous, and Stimuli-Responsive.
Gene Therapy
The most common form of gene therapy involves inserting a normal gene to replace an abnormal gene.
Other approaches include swapping an abnormal gene for a normal one, repairing an abnormal gene, or
altering the degree to which a gene is turned on, or off. The latter approach is often flagged using the
situation "RNA-based therapy.”
17
SITUATION FIELDS (CONTINUED)
Situation
Description
Generic Drug
A generic drug is identical -- or bioequivalent -- to a brand name drug in dosage form, safety, strength, route
of administration, quality, performance characteristics and intended use. It’s usually discounted to the
brand.
A product that would be used principally in a hospital / acute care setting.
Hospital Product
Hostile Takeover Situation
The acquisition of one company by another (called the acquirer) that is accomplished, not by coming to an
agreement with the target company's management, but, by going directly to the company's shareholders or
fighting to replace management in order to get the acquisition approved.
Licensing Opportunity
This is a situation where a company seeks to license a product to a development and/or commercialization
partner - often in multiple territories.
Manufacturing Plant or
Technology
Mature Branded Products
This is a situation where a manufacturing facility or manufacturing technology is available.
Named Patient Candidate
Refers to a drug that is still in clinical trials for a serious disease where there are no effective treatments
available. Such a drug can be a candidate for use on a named patient basis. In many countries, once a drug
has been shown in a trial to be effective it can be used on a named patient basis or "compassionate use"
basis. There are a number of companies that specialize in the distribution of such drugs. See
http://en.wikipedia.org/wiki/Named_patient_programs
Naturals, Nutritionals and
Medical Foods
This flags drug candidates that have either a natural origin or usage as a food product. Quite a few drug
candidates were developed from substances found in nature. Many such candidates can be employed as
drugs if appropriate regulatory steps are taken, or instead may be able to come to market sooner as socalled medical foods or even OTC products because their ingredients are regarded as safe.
A drug candidate where the number of potential patients is small. There is frequently an opportunity for a
high price given the rarity of patients.
Orphan Product
Refers to a situation where a drug has been on the market for some time and is receiving little to no
promotion. Such drug candidates typically generate good cash flow and are highly sought after even though
they may have little to no patent life remaining. Certain types of specialty pharmaceutical companies seek to
enhance the revenues from such drugs through authorized generic programs, renewed promotion,
repositioning of a brand or increases in price.
18
SITUATION FIELDS (CONTINUED)
Situation
Description
OTC / Consumer Product
An over-the-counter pharmaceutical product that is sold directly to consumers through a retail or internet
channel. Also included are other health-related consumer products.
Potential M&A Deal
AvaRx analysts believe that a company is (or will soon be) open to exploring a sale transaction or merger.
Protein Platform
A technology for peptide, antibody engineering or development of other protein types.
Radiopharmaceutical
Radiopharmaceuticals are agents used to diagnose certain medical problems or treat certain diseases. They
may be given to the patient in several different ways. For example, they may be given by mouth, given by
injection, or placed into the eye or into the bladder. Radiopharmaceuticals are radioactive agents.
This asset was recently sold. It will be removed soon from AvaRx listings.
Recently Sold
Research/Drug Technology A technology that can be used for biological or chemistry research in a drug development setting. Also
includes technologies that would directly advance the drug development process.
Reverse Merger Candidate A public company that may have cash but lacks a viable asset. This company is a good candidate for merging
with a private company with an asset. A reverse merger occurs when a private company becomes a public
company by purchasing control of the public company. The shareholders of the private company usually
receive large amounts of ownership in the public company and control of its board of directors. Once this is
complete, the private and public companies merge into one publicly traded company.
RNA-Based Therapy
A therapy that involves RNAi, control of microRNA, antisense technologies or other approaches to the
control of RNA.
Royalties
Royalties are cash flow streams that are generally a percent of the sales of a pharma products. This field
identifies royalties and similar assets for groups that are interested in their acquisition.
Specialty Pharma Marketed Products
Stem Cells
A company or situation where a company with marketed products is open to a transaction.
Stem cells are cells with the potential to develop into many different types of cells in the body. They serve as
a repair system for the body. There are two main types of stem cells: embryonic stem cells and adult stem
cells. A number of business development opportunities listed in AvaRx involve stem cells.
19
ONCOLOGY SITUATION FIELDS
Situation
Description
Oncology - Androgen Modulator Androgen modulators attempt to control the spread of cancer by depriving tumors of sex hormones, such as estrogen,
testosterone,or progesterone.
Oncology - Angiogenesis
Inhibitor
Angiogenesis inhibitors attempt to control the spread of cancer by depriving tumors of vasculature needed for the delivery of
blood and oxygen.
Oncology - Antibody-Drug
Conjugate
Antibody Drug Conjugates or ADCs are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy
for the treatment of people with cancer.
Oncology - B7 Immune
Checkpoint
Immune checkpoints are inhibitory pathways hardwired into the immune system that are crucial for maintaining the level of
immune responses in peripheral tissues in order to minimize collateral tissue damage. A checkpoint protein may create the
opportunity for multiple products to be developed, depending on function.
Oncology - Cancer Metabolism
That cancers display an altered cellular metabolism was first recognized almost a century ago, notably in Otto Warburg's
description of a switch in glucose metabolism from oxidative phosphorylation to glycolysis — the Warburg effect. A number of
companies are developing drugs that promise to disrupt cancer metabolism as a way of shutting down a tumor's growth.
Oncology - Cancer Stem Cells
Cancer stem cell therapies attempt to kill specific progenitor cell types that propagate the growth of a tumor, but do not
themselves form the bulk of the tumor.
Refers to therapies that interfere with the process of cell replication through the cell cycle or, alternatively, trigger cellular
self-destruction (apoptosis).
Refers to therapies that are toxic to cells. Such approaches include various forms of chemotherapy (e.g., docetaxel,
doxorubicin) but can also involve other cell killing methods.
Therapies that cause various types of growth signals to a cancer cell to be turned off (e.g., an EGFR inhibitor).
Oncology - Cell Cycle Arrest /
Apoptotics
Oncology - Cytotoxic
Oncology - Growth Factor
Inhibitors
Oncology - Kinase Inhibitors
Oncology - Targeted Approaches
(Cell Surface Markers)
Oncology - Tumor
Microenvironment / ZFPs
Oncology - Vaccines /
Immunotherapy / Non-B7
Oncology - Vascular Disrupting
Agents
Refers to the broad class of tyrosine kinase inhibitors. These are cell surface markers that are involved in cellular signaling and
are often involved in the propagation of cancer.
Refers to therapies that target a specific cellular marker that is overexpressed on a specific type of cancer.
Refers to therapies that change the environment of a tumor, or that involve zinc finger proteins as a strategy to prevent the
spread of cancer.
Refers to immunologic approaches to cancer that do not involve modulation of the B7 checkpoint system.
Therapies that kill cancer by destroying part, or all of their vasculature, which, in turn, deprives them of a regular supply of
blood and oxygen.
20
HOW TO LIST WITH AVARX

There are two ways to enter a listing into AvaRx:
•
•

Self-Serve: You can use our listing form to add a new entry on your own. The
following pages show you how to do this.
Assisted: If you have a complex entry, or many listings, we can put the listings in for
you – assuming you are Premium Subscriber.
Key Frequently Asked Questions:
Q: What if I would like to list a disease that is not on the list?
A: Let us know and we will set up the indication for you.
Q: Can I enter an undisclosed listing where the listing company and product are not
identified?
A: Yes. To do this you need to be a Premium Subscriber. You will need help from us to
have such entries set up and will need to agree with us on how we can get interested
parties over to you (e.g. forward emails to you).
Q: Can I enter a product as an investment bank, broker or consultant?
A: Yes. You can enter on a self-serve, or assisted basis too, if you are a third party
agent for an owner of a product. You can’t enter listings, however, if your firm is not
retained to represent a product.
21
HOW TO LIST A NEW ENTRY ON YOUR OWN



On the home page, click “Add a Deal
Opportunity” on the lower right hand corner
This will put you into the listing editor for a
new listing

On the Opportunities
page, click “Add
Listing” on the upper
right hand corner
Fill out the form, as appropriate:
•
•
•
•
•
The thumbnail would be a graphic
image of your company’s logo, or an
image of the product’s brand name, if
you prefer.
Name would be the name of the
product
Therapeutic area would be one of the
therapeutic categories in AvaRx
Indication is a disease area
Rights available, Molecule type, Route
of Administration, Phase and Situation
have been previously described.
22
FILLING OUT THE FIELDS









Description – should be a one or two sentence synopsis of the business
development opportunity. Avoid promotional phrasing, such as “amazing”,
but do mention the product name, phase of development, latest clinical
data and results, if relevant, and indication in which it is used.
Situation Overview – should provide an overview of the drug candidate,
as you see fit, including a quick description of the medical need, the drug,
relevant history and where you hope things are going. You could also
comment on partnering status and intentions here. It’s also possible to
comment here on IP, CMC, or other pertinent topics not covered
elsewhere.
Mechanism of Action – should describe MOA and, if desired, links to
publications.
Clinical Trials – should provide information on past and current clinical
trials, including number of patients, disease states, outcomes, etc.
Partners by Region – should indicate which territories have been
partnered already and to whom, and which territories are still available.
Contact – which registered user should be the point of contact for
interested parties.
Company – which company you represent
Visibility – you should generally select registered users, which would make
the entry visible only to registered users in AvaRx. “Anonymous users”
would make the entry available to anyone coming to the site,
“Subdomain” makes entry viewable only to people at your company and
“Subscribers” would make the entry only viewable to premium subscribers
of AvaRx.
Submit – clicking submit at the top of the page will send the asset to our
content team for review and approval.
23
MyAvaRx GIVES YOU FURTHER CONTROL



On the home page, click on MyAvaRx
to get to a control panel for AvaRx.
From the control panel, you can see
any recent alerts set up for you and
also see a list of recent pages visited
and actions taken. This is called your
Activity Log.
Using the blue buttons on the left, you
can make a number of changes:
•
•
•
•
•
You can change your user profile
(e.g., address details)
You can change your account
settings, including your
subscription level
You can set preferences (e.g., how
and whether you get alerts)
See which companies you track
Get into the messaging system
24
USER PROFILE EDITOR


This editor allows you to
set up your bio, address
details, import your
picture and enter your
email.
When you are done using
the editor, it is critical to
click on the “Save” button
(Top right hand corner)
25
KEY CONTACTS ON AVARX TEAM
Margaux Stack-Babich
Craig Ferrier
VP, Knowledge Management
P: 1-212-331-7821
E: margaux@avarx.com
margaux@torreyainsights.com
• Manages content team and
responsible for news /
productions
• Co-Founder of Torreya Insights
• Previously at MSNBC
• B.A. Fordham University
VP, Product Development
P: 1-212-331-7822
E: craig@avarx.com
• Leads product development
• Manages business
development and alliances
• Co-Founder of Torreya Insights
• Past experience in web
startups
• B.S., University of Monaco
Monika Trzcinska, Ph.D.
Mara Grbic Walton, MPH
VP, Research Solutions
P: 1-212-331-7821
E: mtrzcinska@torreyainsights.com
• Leads the research & consulting
business of Torreya Insights
• Frequent contributor of ideas to
AvaRx with interest in CNS
• Previously in business
development at Repligen
• Ph.D., Neuroscience, University
of Ottawa
Director, Knowledge Managemnt
P: 1-212-331-7829
E: mwalton@torreyainsights.com
• Reviews AvaRx content listings
and identifies new listings that
fit client interests.
• Strong interest in oncology and
therapeutics for lifethreatening diseases
• Masters in Public Health,
Columbia University.
Suzanne Schultz
Jason Liberman
Director, Knowledge Solutions
P: 1-212-331-7826
E: sschultz@torreyainsights.com
• Manages relationships with
AvaRx customers
• Assists in marketing, sales and
the customer experience
• Previous experience in
research and medical sales
• B.A. Business, Thomas More
College
Director, Knowledge Products
P: 1-212-331-7841
E: jliberman@torreyainsights.com
• Plays a leadership role in sales
at Torreya Insights
• Maintains relationships with a
number of key customers
• Past experience at American
Orthopedics in Marketing role
• MBA, Hofstra
Chris Opler
Chief Technology Officer
P: 33-640-206-512
E: copler@torreyainsights.com
• Lead information architect for
AvaRx, managing four
developers.
• On Galileo LEOP Software
Team and satellite projects for
the European Space Agency
• Studied at George Mason Univ.
Adam Cooper
Director of Content and QC
P: 1-212-331-7828
E: acooper@torreyainsights.com
• Leads AvaRx content
operations and quality control
• Previously at Conde Nast,
Scholastic & Fenway Partners
• Earned B.S. from U of
Wisconsin in Cartography and
Computer Sci, Phi Beta Kappa
Kristen Frederick
VP, Marketing and Operations
P: 1-212-331-7843
E: kristen@torreya.com
• Manages finance, admin, web
site, trade shows and
marketing for Torreya Insights
• Finance & Marketing
background
• Previously at Cowen & Co.
• MBA, Pace University
26
OTHER SERVICES OFFERED BY TORREYA INSIGHTS
Torreya Insights’ mission is to be a high value information service
provider to business development professionals in the
biopharmaceutical industry. Thus, in addition to AvaRx, Torreya
Insights offers several other services:
Customer Relationship Management (CRM) Solutions. These
are integrated software solutions for out-licensing and biotech
professionals:
Licensing Dynamics – a web-based software system that
combines 16,000 industry contacts for out-licensing, matching
of therapeutic and geographic interests to specific companies
and people, as well as private recording of communications
with those people (emails and phone calls).
Financing Dynamics – a web –based software system that
allows companies in search of capital to find the right investors
for their opportunity. Allows to determine whether money is
available and what are investor’s interests.
Research and Consulting Services This area of Torreya Insights
presently works with customers that want structured assistance
in solving specific problems that use our databases (e.g.,
support in a search & evaluation project in a new therapeutic
area that is structured around AvaRx). We have built a skilled
research team for a growing group of client requests.
27

similar documents